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Abstract
Background: The hypothesis that microbial infections may be linked to mental disorders has long been addressed for
Borna disease virus (BDV), but clinical and epidemiological evidence remained inconsistent due to non-conformities in
detection methods. BDV circulating immune complexes (CIC) were shown to exceed the prevalence of serum antibodies
alone and to comparably screen for infection in Europe (DE, CZ, IT), the Middle East (IR) and Asia (CN), still seeking
general acceptance.
Methods: We used CIC and antigen (Ag) tests to investigate BDV infection in Lithuania through a case-control study
design comparing in-patients suffering of primary psychosis with blood donors. One hundred and six acutely psychotic
in-patients with no physical illness, consecutively admitted to the regional mental hospital, and 98 blood donors from
the Blood Donation Centre, Lithuania, were enrolled in the study. The severity of psychosis was assessed twice, prior
and after acute antipsychotic therapy, by the Brief Psychiatric Rating Scale (BPRS). BDV-CIC and Ag markers were tested
once after therapy was terminated.
Results: What we found was a significantly higher prevalence of CIC, indicating a chronic BDV infection, in patients
with treated primary psychosis than in blood donor controls (39.6 % vs. 22.4 %, respectively). Free BDV Ag, indicating
currently active infection, did not show significant differences among study groups. Higher severity of psychosis prior
to treatment was inversely correlated to the presence of BDV Ag (42.6 vs. 34.1 BPRS, respectively; p = 0.022).
Conclusions: The study concluded significantly higher BDV infection rates in psychotic than in healthy Lithuanians,
thus supporting similar global trends for other mental disorders. The study raised awareness to consider the integration
of BDV infection surveillance in psychiatry research in the future.
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Background
A recent analysis of data from the Global Burden of
Disease study (GBD 2010) revealed that mental and sub-
stance disorders are the fifth leading cause of DALYs (Dis-
ability-adjusted life years) and the leading cause of YLDs
(years lived with disability), accounting for 7.4 % of global
DALYs and 5.6 % of global YLDs [1]. The intriguing hy-
pothesis of an infectious cause of or contribution to men-
tal disorders has been considered for different viruses, e.g.
herpes viruses and schizophrenia [2]. However, a link,
whatsoever, to Borna disease virus (BDV) appeared as a
particularly promising line of research since more than
two decades [3, 4], Pros and Cons of which are still under
debate [5]. Recently, a meta-analysis on infectious agents
and depression further supported BDV as the most rele-
vant candidate agent and found statistical significance that
depressed individuals are 3.25 times more likely to be in-
fected by BDV than healthy [6].
Borna disease virus (BDV-1; genus Bornavirus, species
Mammalian 1 bornavirus) has been found worldwide
[5, 7]. All variants/strains are characterized by highly
conserved single-stranded, non-segmented RNA ge-
nomes (less than 10 kb) of negative polarity which repli-
cate in the nucleus [8], persistently infecting neurons
and glia cells mainly in the central nervous system.
They have been shown to cause neurological diseases in
a wide range of mammals, including Borna disease in
horses and sheep [8, 9]. Human isolates have been
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reported from Germany [10, 11] and Japan [12]. Com-
pared to genetically closely related worldwide BDV (−1)
strains, recently discovered virus species in birds and
reptiles were considerably different [13], including a
variegated squirrel 1 bornavirus (VSBV-1) proposed to
underlie three human cases of fatal viral encephalitis
[14]. Independently, the finding of endogenous Borna-
like N protein elements (EBLNs) which had been
integrated during million years of co-evolution into
germ-lines of humans and their predecessors [15–17]
promoted the “Mood virus hypothesis” linking BDV
with psychiatric diseases [4, 5]. After the early finding of
BDV specific antibodies (Ab) in psychiatric patients
[18], further worldwide evidence could also be added by
the presence of BDV-specific RNA [19–29], and import-
antly by isolation of infectious virus either from blood
cells or brain of mentally ill patients [10, 12]. However,
differing sensitivity levels of antibody and RNA tech-
niques hampered the comparability of reported infec-
tion rates. Failure of detection of any markers in
psychiatric patients occurred as well despite of earlier
reported evidence [22, 30], casting doubts both on tech-
niques and impact of human BDV infection.
The discovery of virus-specific circulating immune com-
plexes (CIC) as the most prevalent variables of BDV infec-
tion in mammals provided both a better insight into
infection dynamics and a new screening instrument which
allowed comparability in epidemiological studies [31]. CIC
are the result of a period of virus replication, release of
abundant virus proteins (N and P; antigen [Ag]) into the
plasma, and subsequent generation of antibodies (Ab) in
the infected host, finally leading to Ag/Ab complexes
which circulate in the blood (CIC). In accord to this dy-
namic process, most of Ab and Ag are bound into CIC,
whereas unbound Ab as well as Ag are less frequent at the
same time point [31].
The determination of CIC and Ag by an ELISA tech-
nique [31] is based on two monoclonal antibodies (mAb)
directed against N- and P-protein [W1, Kfu2] [32], but
specificity has been questioned by those who opposed hu-
man infection [33]. However, their negative findings could
be explained by an inappropriate approach in that affinity-
chromatography lacked a necessary preclearance step [34],
and sensitivity lacked validation through recombinant pro-
teins spiking negative samples in a parallel approach [33].
In contrast, CIC- and Ag-ELISA results could be validated
through comparative use of a different N-protein specific
mAb (Bo18) [35], characterized by other researchers [36].
Specificity of the original mAbs W1 and Kfu2 were further
determined by mapping their conformational epitopes on
N and P proteins, respectively, and sensitivity through re-
combinant N-protein (1.5–3 ng/mL) [37]. Screening for
human BDV-CIC could meanwhile be successfully applied
in European countries, Australia, the Middle East, and
China [38–42], suggesting differing prevalence in healthy
carriers of countries (11 up to 37 %).
The increasing global costs of mental illness at nearly
2.5 billion USD in 2010, with a projected increase to over
6 billion USD by 2030, are associated with a huge eco-
nomic burden for the society and request urgent studies
in this field [43]. Except the Czech Republic [40], no infor-
mation on BDV prevalence exists in East European coun-
tries with regard of these sensitive test systems. How BDV
infection is determined and whether or not the most sen-
sitive systems are applied is of paradigmatic significance,
because pathogenicity is reversely associated with infec-
tion prevalence of the pathogen [37].
The aim of this study was to test Lithuanian in-patients
with primary psychosis upon their admission to the men-
tal hospital for BDV variables (CIC and Ag), and to com-
pare the data with those of blood donors regarded as
controls. Furthermore, the study aimed to evaluate
whether the severity of psychiatric symptoms among in-
patients correlates with the presence or absence of BDV-
specific CIC and Ag. Finally, the study aimed to put the
data in context to those of other countries using the same
infection variables, and thereby may add to whether or




At large 180 female and male in-patients, aged between 18
and 70 years, who were suffering from acute primary
psychosis and consecutively admitted to the Acute Psych-
osis Department of the regional mental hospital in
Lithuania during a 14 months period, were invited to par-
ticipate in this study. The protocol of the study and
subjects’ informed consent forms were approved by the
Kaunas Regional Ethics Committee for Biomedical Re-
search of the Lithuanian University of Health Sciences
(2009-10-12 No. BE-2-17). In sum 156 in-patients agreed
to participate and signed the informed consent form. Exclu-
sion criteria for the study covered history of any significant
or unstable medical condition, diagnosis of psychoactive
drug dependence 6 month before hospital admission, and
electroconvulsive therapy (ECT) 3 months before hospital
admission. Pregnant women or breastfeeding mothers were
excluded as well.
Therefore, only 106 in-patients (59 %) were finally in-
cluded in the study, 45 men and 61 women (mean age
38.4 years; 95 % confidence interval (95 % CI) 35.8–41.0).
They were evaluated as physically healthy, according to
routine physical examination, medical history, routine
blood and urine tests, and provided blood samples for the
assessment of BDV infection markers.
The group of blood donors consisted of 98 individuals,
67 men and 31 women (mean age 31.9 years; 95 % CI
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29.4–34.3). Their blood samples were procured from the
Blood Donation Centre (Kaunas, Lithuania http://
www.kraujodonoryste.lt/) and served as controls. The per-
mission for using the donors’ blood samples was approved
by the Kaunas Regional Ethics Committee for Biomedical
Research of the Lithuanian University of Health Sciences
(2010-09-30 No. P1-72/2009). All blood donors were eval-
uated as healthy according to an advanced blood donor
examination procedure excluding infection with HIV,
HBV or HCV, any severe or unstable medical conditions,
any history or current mental disorders, and any somatic
and psychiatric medications.
Psychiatric evaluation
Psychiatric diagnoses were established according to the cri-
teria of the Diagnostic and Statistical Manual of Mental
Disorders, Fourth Edition, Text Revision (DSM-IV-TR)
[44] using the structured Mini International Neuropsychi-
atric Interview [45]. Patients who met the diagnostic cri-
teria for schizophrenia (295.3; n = 65), brief psychotic
disorder (298.8; n = 20), schizoaffective disorders (295.7; n
= 14), and schizophreniform disorders (295.4; n = 7) were
assigned as patients with primary psychosis. Thirty three
(31.1 %) out of the 106 in-patients with primary psychosis
experienced the first psychotic episode during their life-
time; the other 73 patients (68.9 %) were in psychotic re-
lapses. The duration of mental disorder prior to this
psychotic episode was from 0 to 40 years; median was
2 years, interquartile range (IQR) was between 0 and
2 years. The duration of hospitalization during acute anti-
psychotic therapy lasted from 4 to 55 days (mean duration:
29 ± 10 days). All 106 patients received standard anti-
psychotic medications validated to treat acute psychosis.
The vast majority of patients (n = 103) received additional
treatment with benzodiazepines and 26 patients additional
treatment with antidepressants. The severity of psychotic
symptoms was assessed twice by the Brief Psychiatric Rat-
ing Scale (BPRS): (1) the next morning after hospital ad-
mission, prior to antipsychotic therapy, and (2) on the last
day of hospitalization, after acute psychosis treatment was
terminated. The 18 BPRS items total score rating from 0
(symptoms not present) to 6 (extremely severe symptoms)
was calculated. The change in total BPRS scores indicating
the efficacy of the psychosis treatment was calculated by
subtracting total BPRS scores after treatment from those
before treatment. All psychiatric evaluations were carried
out by the same trained psychiatrist. Demographic data
and clinical diagnoses were summarised in Table 1.
Serological measurements
Venous blood samples from the in-patients’ group were
drawn on the last morning of hospitalisation, after termin-
ation of acute psychosis treatment. Blood samples from the
control group were collected at the Blood Donation Centre
(Kaunas, Lithuania). All blood samples were centrifuged
and sera stored at −20 °C. The amount of BDV-specific
CIC and Ag were evaluated at a certified commercial med-
ical laboratory (Diamedis, Bielefeld, Germany), using the
standardised and patented ELISA technique [31].
Enzyme immuno assays (EIAs)
Following the concept of maximum versatility, all EIAs in-
cluding the CIC test used the same solid phase support,
volume per vial (100 μl), and buffers, as well as the same
initial coating steps (1 and 2), as described previously [31].
The published protocol was applied throughout as de-
tailed below.
CIC assay
Step 1—polystyrene microtiter format Maxisorp Immuno
Modules (Nunc, Roskilde, Denmark) were coated with
1.8 μg ml−1 of AffiniPure Goat Anti-Mouse IgG,
FcFragment-specific (adsorbed against human, bovine,
and equine serum proteins; Jackson Immuno Research,
Westgrove, PA, USA), in 10 mM sodium phosphate and
250 mM sodium chloride, pH 7.6, for 1 h at 37 °C (or
overnight at 4 °C). Step 2—after washing (three times in
0.9 % sodium chloride + 0.05 % Tween 20, Ultrawash Plus,
Dynatech Labs, Chantilly, VA, USA), BDV p40 and p24
mouse monoclonal antibodies (moAbs) (W1, Kfu2, hy-
bridoma supernatants IF-antibody titer 1:2000), each di-
luted 1:500 in PBS (pH 7.2) + 0.05 % Tween 20 (PBS-T),
were incubated for 1 h at 37 °C (or overnight at 4 °C). Step
3—after washing, serum samples, diluted 1:20 and serially
two-fold in PBS-T, were incubated for 1 h at 37 °C. Step
4—after washing, Alkaline Phosphatase (AP)-conjugated
AffiniPure Goat Anti-Human IgG, Fc Fragment-specific
(adsorbed against mouse, bovine, and equine serum pro-
teins; Jackson Immuno Research, Westgrove, PA, USA),
diluted 1:3000 in 20 mM Tris-buffered saline pH 8.0 +
0.05 % Tween 20 (TBS-T), was incubated for 1 h at 37 °C.
Step 5—after washing, freshly prepared substrate p-nitro-
phenylphosphate (pNPP) (1 mg ml−1) in 1 M diethanola-
mine buffer (pH 9.8) + 0.5 mM magnesium chloride was
incubated for up to 5 min at room temperature under vis-
ible control (negative and buffer control remaining
colourless). Step 6—the enzymatic reaction was stopped
by the addition of 50 µl of 3 M sodium hydroxide, and
read at 405 nm in a Dynatech Microplate Reader MRX.
Antigen assay
BDV antigens p40 (N-protein) and p24 (P-protein)
present in blood plasma (pAg; N/P heterodimers in-
cluded) were determined by the following EIA-protocol:
Steps 1 and 2—as CIC assay. Step 3—after washing, na-
tive serum samples, diluted 1:2 and serially two-fold in
PBS-T, were incubated for 2 h at 37 °C. Step 4—after
washing, polyclonal rabbit anti-BDV serum (IFA-titer
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1:10 000), diluted 1:1000 in PBS-T, was incubated for
2 h at 37 °C. Step 5—after washing, AP-conjugated Affi-
niPureGoat Anti-Rabbit IgG, FcFragment-specific
(adsorbed against human serum proteins; Jackson
Immuno Research, Westgrove, PA, USA), diluted 1:3000
in TBS-T was incubated for 1 h at 37 °C. After washing,
steps 5 and 6 followed that of the CIC assay.
Evaluation of assay results
Both assays made use of the same cut-off value to distin-
guish between positive and negative results, facilitating
user friendly direct comparison of extinction values from
different assays. This was possible through adapting the
initial sample dilutions in that 1:20 was used for the CIC
assay and 1:2 for the Ag assay, thereby considering that
CIC are likely to occur at ten times higher concentrations
as free antigen in host’s serum or plasma. Equal extinction
values of CIC and Ag in the same sample are therefore in-
dicative of a ten times as high CIC than Ag amount at a
given time-point of infection.
Both tests were scored negative at an extinction of ≤0.1.
This cut-off was determined on the basis of randomly se-
lected negative human sera in Germany (n = 44) of which
the mean extinction plus three standard deviations (SD)
were calculated. The data for the CIC assay were as follows:
mean 0.043, SD 0.019, 3xSD 0.057 resulting in a cut-off of
0.100. The data for the Ag assay were as follows: mean
0.045, SD 0.017, 3xSD 0.051 resulting in a cut-off of 0.096.
These enzyme-linked immunosorbent assays to test
CIC and Ag have been independently proposed as a kind
of “gold standard” for monitoring BDV infections [46].
However, a general acceptance could not be achieved so
far, as already detailed above. The presence of CIC with
or without antibodies indicates a chronic infection; the
presence of Ag, with or without CIC at the same time, is
indicative for a currently active infection [4].
Statistical analysis
Demographic characteristics of in-patients and blood do-
nors are presented as mean (95 % CI [confidence interval])
for continuous variables and as number (percentages) for
categorical variables. For ratio comparisons between BDV
infection markers, namely CIC and Ag values of patients
and healthy blood donors, the chi-square test (χ2) was ap-
plied. BPRS scores before and after treatment, delta (Δ)
BPRS, duration (years) of mental disorder, and duration
(days) of hospitalization were compared in the BDV- CIC
positive and BDV- CIC negative as well as in the BDV- Ag
positive and BDV- Ag negative groups using the Student’s
t-test. Linear regression analyses were applied to examine
whether age, gender, duration of mental disorder, treatment
with antidepressants, or Borna disease virus (BDV) infec-
tion markers (CIC and/or Ag) predicted the severity of
psychosis at baseline, before treatment with antipsychotics.
Data were analysed using the SPSS 21.0 for Windows, and
a p-value of < 0.05 was considered to be significant.
Results
According to the demographic characteristics (Table 1)
the study groups differed according to age and gender in
that the in-patients’ group was older (F [1] = 12.825;
p < 0.001) with higher prevalence of women (χ2 = 3.8; df = 1;
p <0.001). This is, however, a frequently observed mismatch
Table 1 Demographic characteristics of study populations
Factors In-patients Blood donors
Total number, n 106 98
Mean age, years (95 % CI) 38.4 (35.8–41.0) 31.9 (29.4–34.3)
Women, n (%) 61 (57.5) 31 (31.6)
Primary diagnosis (DSM-IV-R), n (%)
Schizophrenia (295.3) 65 (61.3)
Brief psychotic disorder (298.8) 20 (18.8)
Schizoaffective disorder (295.7) 14 (13.2)
Schizophreniform disorder (295.4) 7 (6.6)
First episode, n (%) 33 (31.1)
Psychotic relapses, n (%) 73 (68.9)
Prior-study duration of disorder, years (median) 0–40 (2)
Duration of hospitalization, days (SD) 29 (10)
Standard antipsychotic treatment, n (%) 106 (100)
Additional treatment with benzodiazepines, n (%) 103 (97.2)
Additional treatment with antidepressants, n (%) 26 (24.5)
Diagnoses according to DSM-IV-R criteria using Mini International Neuropsychiatric Interview (Ref. [44, 45])
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in studies which used blood donors as control group [3, 4],
and could rarely be circumvented [41].
Seroprevalence data of BDV infection markers among
in-patients with primary psychosis and blood donor con-
trols are presented in Table 2. We found a significantly
higher prevalence of BDV-CIC in the group of treated
in-patients with primary psychosis than in the healthy
donors (39.6 % vs. 22.4 %, respectively, χ2 = 7.0; df = 1;
p = 0.008). According to gender, we found a significantly
higher prevalence of BDV-CIC among women (χ2 = 2.5;
df = 1; p = 0.001), but not among men (χ2 = 3.0; df = 1;
p = 0.086). In contrast to CIC, BDV- Ag did not show
significant differences among the two study groups
(6.6 % Ag positives in the patients vs. 2.0 % in the con-
trols; χ2 = 2.5; df = 1; p = 0.113). BDV- Ag was found in
six in-patients with psychosis relapses (four diagnosed
with schizophrenia and two with schizoaffective
disorder) and one patient with a first time acute psych-
otic episode diagnosed as a brief psychotic disorder. The
age in BDV- Ag positives in-patients ranged from 20 to
41 years. Two blood donors, evaluated as BDV- Ag posi-
tives were men aged 25 and 50 years old, respectively.
Both assays were providing quantitative measures in
that extinction values corresponded to the relative
amounts of CIC and Ag present at the time of serum
collection, thereby considering that the relative CIC
amount is ten times as high as that of Ag given
different serum dilutions. CIC-Ag pairs and their
distribution in patients and controls are illustrated in
Fig. 1, indicating fairly similar distribution patterns
between the two groups.
To further analyse to which extent CIC and Ag quan-
titative levels were correlated we did regression analyses
of CIC vs. Ag values illustrated by scatterplots in Fig. 2.
Not only could be demonstrated that CIC and Ag
markers were strongly correlated to each other, but also
that this correlation held true for both study groups,
given the equally high correlation coefficients of r = 0.76
and 0.77, respectively.
We further investigated whether clinical characteristics
of patients, particularly the severity of psychotic symp-
toms, are related to either BDV- CIC, BDV- Ag or both
these markers (Table 3).
What we surprisingly found was an inverse correlation of
BDV antigen and clinical severity at baseline (prior to ther-
apy). Using the BPRS scores, severity was higher among in-
patients whose blood was negative for BDV- Ag than in
those patients with a positive BDV- Ag test (42.6; 95 % CI
40.6–44.5) vs. 34.1; 95 % CI 27.7–40.5), respectively (F [1]
= 5.393; p = 0.022). After adjustment for age, these results
remained statistically significant (p = 0.047). In contrast,
BDV-CIC were unrelated to clinical severity at baseline.
Likewise, clinical efficacy of antipsychotic therapy (changes
in psychosis symptoms severity; ΔBPRS) was unrelated to
the presence or absence of BDV-CIC. We found no evi-
dence for any difference between BDV-CIC positive in-
patients and BDV-CIC negative in-patients with regard to
either symptom severity or improvement through anti-
psychotic therapy.
We finally conducted a multivariate analysis to examine
any relationship between psychosis severity at baseline and
predictive factors (Table 4). The only significant variable for
Table 2 Seroprevalence of BDV-specific circulating immune complexes (CIC) and antigen (Ag)
In-patients Blood donors-controls p-value Extinction values
Total number, n 106 98
CIC positive, n (%) 42 (39.6) 22 (22.4) 0.008
Men, n (%) 16 (35.6) 14 (20.9) 0.086
Women, n (%) 26 (42.6) 8 (25.8) 0.001
CIC negative, n (%) 64 (60.4) 76 (77.6) 0.027 ≤0.12
CIC weak positive, n (%) 15 (14.2) 12 (12.2) >0.12–0.15
CIC positive+, n (%) 19 (17.9) 8 (8.2) >0.15–0.30
CIC positive++, n (%) 8 (7.5) 2 (2.0) >0.30–0.60
Ag positive, n (%) 7 (6.6) 2 (2.0) 0.113
Men, n (%) 5 (11.1) 2 (3.3) 0.082
Women, n (%) 2 (28.6) 0 (0) 0.308
Ag negative, n (%) 99 (93.4) 96 (98.0) 0.255 ≤0.12
Ag weak positive, n (%) 5 (4.7) 1 (1.0) >0.12–0.15
Ag positive+, n (%) 2 (1.9) 1 (1.0) >0.15–0.30
Extinction values read at 405 nm microplate ELISA reader
p-values < 0.05 indicating statistical significance between groups. Significant differences are marked in bold
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an adjusted correlation to BPRS scores prior to treatment
was negatively scored BDV antigen p = 0.044), thereby con-
firming above data.
Discussion
This study is the first undertaking to estimate the sero-
prevalence of BDV (−1) infection in Lithuania by using a
cross-sectional case control study design. The focus was
first to investigate whether and to which levels BDV infec-
tion occurs in Lithuania, and secondly whether and how
BDV infection variables CIC and Ag differs between in-
patients with acute primary psychosis and healthy blood
donors. The decision to determine circulating immune
complexes (CIC) instead of widely used RNA and anti-
bodies was based on higher sensitivity than achievable
through the other two variables, together with high repro-
ducibility and specificity of the enzyme immune assay
(EIA) based test system [31, 37]. Comparability across
countries was another profound advantage over prevailing
approaches. Notably, we not only applied the virus- and
host-related BDV-CIC assay as basic screening test but
simultaneously determined BDV-antigen (Ag) as solely
virus-derived variable in each sample.
The study not only confirmed the existence of BDV in-
fection in Lithuania but interestingly found that the CIC
prevalence in healthy Lithuanians ranged at the lowest
level of 22.4 % so far reported from Europe, differing par-
ticularly from the high level of 37 % in another Eastern
European country [40]. The result of one-fifth of healthy
carriers did, however, support the concept that BDV is a
Fig. 1 Distribution of quantitative BDV infection markers (CIC and Ag). a CIC-Ag pairs among patients with primary psychosis, and b blood
donors; CIC = circulating immune complexes, Ag = antigen. Solid lines represent cut-off values of either CIC assay (horizontal) or Ag assay (vertical)
Fig. 2 Correlation between quantitative BDV infection markers (CIC vs. Ag). Scatterplots of CIC vs. Ag extinction values determined at serum
dilutions of 1:20 and 1:2, respectively; CIC and Ag abbreviations in Fig. 1. a data of in-patients, b data of blood donors; r = regression coefficient,
p = significance level, r2 square regression coefficient
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moderate pathogen with a majority of sub-clinical infec-
tions [37].
According to patients which are a minority in popula-
tions, our study revealed a BDV prevalence of 39.6 %
based on CIC which was significantly different from that
of controls. Our study thus confirmed what has been re-
ported from psychiatric patient groups in other countries
(e.g. Germany, Iran, and China) using the same virus vari-
ables, all of which found a significantly higher burden of
BDV infection compared to controls [4, 41, 42]. Whereas
the German and Chinese studies focused solely on pa-
tients with Major depressive disorder (MDD) and bipolar
depression (BD) [31, 42], the Iranian in-patients’ group
additionally covered 33 patients diagnosed as having
schizophrenia or schizoaffective psychosis [41]. It is note-
worthy to mention that Iranian patients with schizophre-
nia displayed only half the CIC prevalence detected in
depressed patients with mood disorders (22 % vs. 44 %)
which was also much lower than in this study (39.6 %).
Free BDV antigen in plasma, indicating currently active
infection, reached levels of 5.6 % in Iranian schizophrenic
patients, similar to our findings (6.6 %).
BDV- Ag prevalence values were too low to reach sig-
nificant difference to controls in our study, and were even
inversely correlated to psychotic symptoms’ severity at
baseline. Possibly, the very low number of patients who
were Ag-positive accounted for this somewhat tenuous
finding. Moreover, it should be kept in mind that the
maintenance of free antigen in plasma is largely depending
on the speed and efficacy of the host to generate anti-
bodies resulting in CIC formation [31]. The antibody EIA-
test has not been available for this study. What could be
clearly demonstrated, however, was the strong correlation
of CIC and Ag markers which held true for both study
groups, confirming the high interdependence of these var-
iables in the course of BDV infection.
This study also evaluated whether the presence or ab-
sence of BDV-CIC determined after antipsychotic therapy
correlated with severity as well as treatment variables.
What we found was no correlation at all, neither in terms
of severity codes by BPRS scores matching the Ag data,
nor with regard to any additional treatment with benzodi-
azepines and/or antidepressants. We could, however, not
exclude the possibility that antipsychotic treatment impact
antibody levels.
The here found lack of correlation is largely contrasting
previous findings covering in- and out MDD and BD pa-
tients suffering from very severe to moderate depressive
episodes, whose CIC and Ag prevalence as well as marker
levels were clearly corresponding to severity [4, 31]. Given
comparability based on the same infection variables, this
evaluation led us to speculate that BDV infection might
involve more contributing links to depression (defined as
MDD or BD) rather than to psychotic disorders. The











Total number, n 42 64 7 99
Mean age (95 % CI), years 35.6 (31.9–39.40) 40.2 (36.6–43.8) 0.091 29.3 (21.7–36.8) 39.1 (36.1–41.8) 0.067
Gender 0.462 0.108
Men, n (%) 16 (38.1) 29 (45.3) 5 (71.4) 40 (40.4)
Women, n (%) 26 (61.9) 35 (54.7) 2 (28.6) 59 (59.6)
BPRS before (95 % CI), score 40.6 (37.6–43.6) 42.9 (40.5–45.3) 0.225 0.375 34.1 (27.7–40.5) 42.6 (40.6–44.5) 0.022 0.047
BPRS after (95 % CI), score 21.2 (18.8–23.6) 21.2 (19.3–23.2) 0.981 0.755 16.8 (10.6–23.1) 21.6 (20.0–23.1) 0.113 0.197
ΔBPRS (95 % CI), score 19.4 (17.5–21.3) 21.7 (19.9–23.5) 0.094 0.115 17.3 (10.4–24.2) 21.0 (19.6–22.4) 0.161 0.195
Duration of mental disorder (95 % CI), years 5.2 (3.2–7.3) 6.7 (4.6–9.0) 0.356 0.882 9.0 (2.2–15.8) 5.9 (4.3–7.6) 0.337 0.050
Duration of current hospitalization (95 % CI),
days
29.2 (26.0–32.3) 29.4 (27.0–31.8) 0.915 0.703 33.9 (24.7–43.0) 29.0 (27.0–30.9) 0.201 0.312
Abbreviations: BPRS Brief Psychiatric Rating Scale, ΔBPRS BPRS score before minus, BPRS score after treatment, CIC circulating immune complexes; Ag antigen
p* statistical significance <0.05 significant differences are marked in bold; p# adjusted for age
Table 4 Linear regression model for factors influencing severity
of psychotic symptoms at baseline
Factors Dependent variable BPRS at baseline
β p
R2 = 0.127 0.041
Gender 0.078 0.443
Age, years 0.043 0.710
Antidepressants −0.175 0.075
Duration of mental disorder, years 0.167 0.130
BDV- CIC −0.069 0.502
BDV- Ag −0.210 0.044
Abbreviations: BDV- CIC circulating immune complexes and BDV- Ag antigen,
infection markers of BDV
BPRS Brief Psychiatric Rating Scale
p < 0.05 indicate statistical significance is marked in bold
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Australian finding of high levels of IL-6 (>120 pg/mL) cor-
relating with BDV antibodies in depressed patients but
not in blood donors provided additional support along
these lines [39]. Previous studies including schizophrenic
patients, either using BDV antibody or RNA detection
techniques or both, had revealed highly varying prevalence
rates between 2.1 % in Poland [25], 12 % in Taiwan [24],
14 % in Germany [20], up to 22 % [26] and 45 % in Japan
[23]. A more recent Chinese study found 9.9 % schizo-
phrenic patients RNA-positive by a p24 real-time RT-PCR
[29]. Lack of comparability, characteristic for many inter-
esting studies, had not allowed to evaluate correlative evi-
dence, whatsoever, for defined psychiatric diseases and
BDV infection.
The strength of our study first lied in its high comparabil-
ity with studies in other countries which were based on the
determination of the same infection variables, including the
most prevalent CIC. Secondly, our study investigated clinic-
ally well characterised patients with acute psychosis, and
thus allowed to investigate illness- and severity-related cor-
relations to BDV infection. Thirdly, our study included de-
fined blood donors as healthy controls, and thus allowed to
compare the percentage of silent carriers in Lithuania de-
tected by CIC with those in other parts of the world.
The limitations of our study lied in the rather small
number of subjects, the cross-sectional design, and the age
mismatch of patients and control groups weakening the
case-control approach. However, this kind of limitations
was applying to quite a number of infection prevalence
studies. The lack of general acceptance of the test systems
is a clear disadvantage. However, doubts raised by an in-
appropriate procedural evaluation [33] appeared to be in-
valid as thoroughly addressed here and through previous
specificity proofs [37]. Moreover, this study could clearly
confirm the strong correlation of CIC and antigen in either
study group adding another validity check. This may con-
tribute to overcome current reluctance in the future.
Conclusion
In conclusion, Lithuanians appeared to match with BDV in-
fection patterns so far reported worldwide [31, 38–42]. The
study added to comparability between countries by using
highly prevalent CIC and a robust, easy-to-use and specific
assay system [37] which is still competing for acceptance.
One fifths of healthy Lithuanians were determined as sub-
clinically infected, the so far lowest level in Europe, con-
trasting the significantly elevated prevalence in psychotic
patients which, however, did not correlate with symptom
severity. This and other case-control studies did not provide
the capacity to clarify the unsettled role of BDV infection in
mental disorders, but may be able to raise awareness to
neglected potential risks. Given the increasing contribution
of mental disorders to the global burden of disease [1] and
the huge related health care costs [43], our study supports
the earlier request of integrating BDV infection surveillance
in psychiatry research [4]. Considering the variations in dif-
ferent countries, future studies should include further
population variables such as the socio-economic status to
address the differences that exist across countries.
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